Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Neovascular (Wet) Age-Related Macular Degeneration (AMD) requires long-term anti-VEGF injections to suppress leaky blood vessels. In 2026, a major challenge is "Treatment Discontinuation"?when patients stop injections because their eye looks "dry." Understanding the speed of recurrence is critical for preventing permanent vision loss when the disease reactivates.
read more about wet amd recurrence ...Clinical data from 2026 indicates that approximately 53 percent of Wet AMD patients experience a recurrence of fluid within 12 months of stopping their injections. Even in patients who achieved a "completely dry" macula for three consecutive visits, the risk of the blood vessels "waking up" is high. This confirms that for the majority of patients, anti-VEGF therapy is a suppression rather than a permanent cure.
Longitudinal cohort studies show that the median time to retreatment is approximately 3.3 years for those who successfully "graduated" from a treat-and-extend protocol. However, for those who stopped treatment prematurely (lost to follow-up), the median time for a vision-threatening "flare" is only 14 months. 1 in 3 patients who stop treatment will require a rescue injection within the first year.
A recurrence is often accompanied by a rapid drop in clarity. Statistics show that the average visual acuity drops from 20/50 (at the time of stopping) to 20/60 or 20/70 during a recurrence. While 90 percent of patients recover their baseline vision if treated within 4 weeks of the flare, 3 percent of the population suffers a permanent, non-recoverable loss due to subretinal scarring.
Treatment fatigue is a major factor in 2026. Data reveals that 60 percent of Wet AMD patients become "non-persistent" or discontinue treatment within two years of diagnosis. The primary reasons cited are the "burden of travel" (45%) and the "fear of the needle" (20%). This high dropout rate is the leading cause of preventable blindness in the AMD population globally.
Current research suggests that only about 37 percent of eyes meet the clinical criteria for safe treatment cessation. In 2026, "safe cessation" is defined as a stable retina for at least one year on a 12-week injection interval. Even in this "safe" group, the recurrence rate remains at 29 percent, highlighting the need for mandatory home-monitoring for any patient who stops active injections.
In 2026, we know that Wet AMD is like a fire that is currently "smoldering" under control. The shots are what keep the fire from flaring up. If you stop the shots just because the scan looks clear, the underlying VEGF protein builds up again, and in 50% of people, the leaking starts again within a year, often causing a sudden blur.
Taking a "holiday" from injections is very risky. Data from 2026 shows that 20% of patients who miss just two months of treatment show a return of fluid. Even a short break can lead to microscopic scarring that permanently reduces how well you will see, even if you start the shots again later.
You usually won't feel it at first. The first signs are often subtle, like straight lines (doorframes) looking slightly wavy. In 2026, the best way to catch a recurrence is using a digital "Amsler Grid" at home every morning. If you see a change, you need an injection within 48 hours to prevent a permanent scar.
See your retina specialist immediately if you notice a new gray spot, a "shimmering" area, or increased distortion in your central vision after stopping or delaying an injection. These are the primary indicators of an active neovascular recurrence that must be treated within days to maximize the chance of vision recovery.